NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT04553133 2026-04-13PF-07104091 as a Single Agent and in Combination TherapyPfizerPhase 2 Active not recruiting157 enrolled